Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636400 | 1.00 | TRPV4 (0.35) | TRPV4NOTUMLMNACA2P2RX7 | |
| SCHEMBL30358807 | 0.77 | TRPV4 (0.35) | TRPV4NOTUMLMNAP2RX7 | |
| SCHEMBL14794846 | 0.77 | TRPV4 (0.35) | TRPV4NOTUMLMNAP2RX7 | |
| SCHEMBL17141408 | 0.76 | TRPV4 (0.38) | TRPV4NOTUMLMNAP2RX7KDM4E | |
| SCHEMBL31099016 | 0.76 | NOTUM (0.41) | TRPV4NOTUMP2RX7KDM4E | |
| SCHEMBL17407889 | 0.76 | TRPV4 (0.34) | TRPV4NOTUMP2RX7KDM4E | |
| SCHEMBL1451444 | 0.76 | NOTUM (0.41) | TRPV4NOTUMP2RX7KDM4E | |
| SCHEMBL1506604 | 0.76 | LMNA (0.42) | TRPV4NOTUMLMNAKDM4E | |
| SCHEMBL24468865 | 0.73 | TRPV4 (0.40) | TRPV4NOTUMLMNAP2RX7KDM4E | |
| SCHEMBL19155972 | 0.73 | LMNA (0.36) | TRPV4NOTUMLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
| CN-117062804-A | 1, 3-substituted cyclobutyl derivatives and their use | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20220324811-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2022-10-13 | — | — | US | disclosed |
| WO-2022201097-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| EP-2027124-B1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2027124-B1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-03 | — | — | EP | disclosed |
| US-8178530-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-15 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-7893058-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| US-7893058-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| US-7893058-B2 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-22 | — | — | US | disclosed |
| EP-2027124-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-02-25 | — | — | EP | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | TRPV4 6/4885NOTUM 1562/4885LMNA 3905/4885 |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | TRPV4 6/4885NOTUM 1562/4885LMNA 3905/4885 |
| US-20220324811-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | TRPV4 6/4885NOTUM 1562/4885LMNA 3905/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | TRPV4 6/4885NOTUM 1562/4885LMNA 3905/4885 |
| US-20110092497-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IKZF3, IRAK2, IRAK1 | TRPV4 1835/4885NOTUM 3078/4885LMNA 1882/4885 |
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | TRPV4 1835/4885NOTUM 3078/4885LMNA 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.